Jack V. Mills, Avigail Taylor, Reema Singh, Jinseon Kim, Simon Engledow, Richard Colling, Clare Verrill, Ian G. Mills, Valentine M. Macaulay
{"title":"临床前列腺癌中染色质增强子和启动子区域IGF-1R全基因组募集的检测","authors":"Jack V. Mills, Avigail Taylor, Reema Singh, Jinseon Kim, Simon Engledow, Richard Colling, Clare Verrill, Ian G. Mills, Valentine M. Macaulay","doi":"10.1002/cam4.71257","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Nuclear insulin-like growth factor-1 receptor (IGF-1R) undergoes IGF-induced recruitment to cancer cell chromatin in vitro and associates with advanced prostate cancer (PCa) stage in clinical tissue, prompting this investigation of IGF-1R chromatin recruitment in vivo.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Human tissues surplus to diagnostic need were obtained from consenting patients undergoing transurethral resection of the prostate (TURP) or radical prostatectomy (RP). Initial tissue samples were processed for H3K4me1-positive control ChIP to optimise homogenisation, fixation and ChIP conditions. Following successful method optimization, IGF-1R and H3K4me1 ChIP-seq was performed on six treatment-naïve localized PCa samples, along with parallel IGF-1R immunohistochemistry analysis. MACS2 and LanceOtron peak callers were used to identify binding sites from ChIP-seq data and MEME Suite was used to identify an IGF-1R binding motif. In vitro chromatin immunoprecipitation qPCR (ChIP-qPCR) was used for ChIP-seq data validation.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified 5743 unique IGF-1R binding sites, with 37% within 3 kb of gene transcription start sites (TSSs). Of these sites, 72.3% coincided with enhancer mark H3K4me1, suggesting regulatory function. Motif analysis identified an IGF-1R consensus binding motif for the first time, with a sequence resembling that of the insulin receptor and PITX2 transcription factor binding motifs, supporting functional similarities. In vitro ChIP-qPCR confirmed IGF-1R recruitment to a site identified in vivo in the <i>RRM2</i> TSS, a gene involved in DNA replication and repair and regulated by the IGF-axis, highlighting potential regulatory function of nuclear IGF-1R.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Overall, these data represent the first characterization of genome-wide IGF-1R recruitment in PCa tissue and are consistent with a transcriptional regulatory role, further elucidating the contribution of nuclear IGF-1R to advanced clinical stage.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483945/pdf/","citationCount":"0","resultStr":"{\"title\":\"Detection of Genome-Wide IGF-1R Recruitment to Enhancer and Promoter Regions of Chromatin in Clinical Prostate Cancers\",\"authors\":\"Jack V. Mills, Avigail Taylor, Reema Singh, Jinseon Kim, Simon Engledow, Richard Colling, Clare Verrill, Ian G. Mills, Valentine M. Macaulay\",\"doi\":\"10.1002/cam4.71257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Nuclear insulin-like growth factor-1 receptor (IGF-1R) undergoes IGF-induced recruitment to cancer cell chromatin in vitro and associates with advanced prostate cancer (PCa) stage in clinical tissue, prompting this investigation of IGF-1R chromatin recruitment in vivo.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Human tissues surplus to diagnostic need were obtained from consenting patients undergoing transurethral resection of the prostate (TURP) or radical prostatectomy (RP). Initial tissue samples were processed for H3K4me1-positive control ChIP to optimise homogenisation, fixation and ChIP conditions. Following successful method optimization, IGF-1R and H3K4me1 ChIP-seq was performed on six treatment-naïve localized PCa samples, along with parallel IGF-1R immunohistochemistry analysis. MACS2 and LanceOtron peak callers were used to identify binding sites from ChIP-seq data and MEME Suite was used to identify an IGF-1R binding motif. In vitro chromatin immunoprecipitation qPCR (ChIP-qPCR) was used for ChIP-seq data validation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We identified 5743 unique IGF-1R binding sites, with 37% within 3 kb of gene transcription start sites (TSSs). Of these sites, 72.3% coincided with enhancer mark H3K4me1, suggesting regulatory function. Motif analysis identified an IGF-1R consensus binding motif for the first time, with a sequence resembling that of the insulin receptor and PITX2 transcription factor binding motifs, supporting functional similarities. In vitro ChIP-qPCR confirmed IGF-1R recruitment to a site identified in vivo in the <i>RRM2</i> TSS, a gene involved in DNA replication and repair and regulated by the IGF-axis, highlighting potential regulatory function of nuclear IGF-1R.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Overall, these data represent the first characterization of genome-wide IGF-1R recruitment in PCa tissue and are consistent with a transcriptional regulatory role, further elucidating the contribution of nuclear IGF-1R to advanced clinical stage.</p>\\n </section>\\n </div>\",\"PeriodicalId\":139,\"journal\":{\"name\":\"Cancer Medicine\",\"volume\":\"14 19\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483945/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71257\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71257","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Detection of Genome-Wide IGF-1R Recruitment to Enhancer and Promoter Regions of Chromatin in Clinical Prostate Cancers
Introduction
Nuclear insulin-like growth factor-1 receptor (IGF-1R) undergoes IGF-induced recruitment to cancer cell chromatin in vitro and associates with advanced prostate cancer (PCa) stage in clinical tissue, prompting this investigation of IGF-1R chromatin recruitment in vivo.
Methods
Human tissues surplus to diagnostic need were obtained from consenting patients undergoing transurethral resection of the prostate (TURP) or radical prostatectomy (RP). Initial tissue samples were processed for H3K4me1-positive control ChIP to optimise homogenisation, fixation and ChIP conditions. Following successful method optimization, IGF-1R and H3K4me1 ChIP-seq was performed on six treatment-naïve localized PCa samples, along with parallel IGF-1R immunohistochemistry analysis. MACS2 and LanceOtron peak callers were used to identify binding sites from ChIP-seq data and MEME Suite was used to identify an IGF-1R binding motif. In vitro chromatin immunoprecipitation qPCR (ChIP-qPCR) was used for ChIP-seq data validation.
Results
We identified 5743 unique IGF-1R binding sites, with 37% within 3 kb of gene transcription start sites (TSSs). Of these sites, 72.3% coincided with enhancer mark H3K4me1, suggesting regulatory function. Motif analysis identified an IGF-1R consensus binding motif for the first time, with a sequence resembling that of the insulin receptor and PITX2 transcription factor binding motifs, supporting functional similarities. In vitro ChIP-qPCR confirmed IGF-1R recruitment to a site identified in vivo in the RRM2 TSS, a gene involved in DNA replication and repair and regulated by the IGF-axis, highlighting potential regulatory function of nuclear IGF-1R.
Conclusion
Overall, these data represent the first characterization of genome-wide IGF-1R recruitment in PCa tissue and are consistent with a transcriptional regulatory role, further elucidating the contribution of nuclear IGF-1R to advanced clinical stage.
期刊介绍：
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Biology:
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery.
Cancer Prevention:
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach.
Bioinformatics:
Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers.
Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
